BCL2A1 and melanoma: More interestingly, KO of TRIM17 restored sensitivity to PLX4720 in resistant melanoma cells, by relieving the inhibition of TRIM28-mediated ubiquitination of BCL2A1 and thereby by reducing BCL2A1 level [69].